NSE · SPARC · Pharmaceuticals
Sun Pharma Advanced Research Company Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹40 Cr with net profit ₹-21 Cr — a -52.56% net margin, versus 82.17% the period before.
Shareholding
As of 2026-09-30
- Promoter65.67%
- Public30.48%
- FII3.75%
- DII0.11%
1,41,992 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.68× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Miscellaneous · ranked #59 of 552 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| National Stock Exchange Of India Ltd. | ₹4,12,966 Cr | 46.19 | 12.86 | 22.8% | 64.54% |
| Adani Ports & Special Economic Zone Ltd. | ₹3,92,295 Cr | 29.52 | 4.09 | 13.32% | 32.43% |
| Eternal Limited | ₹3,06,302 Cr | 622.35 | 9.77 | 1.58% | 0.63% |
| Vedanta Aluminium Metal Limited | ₹1,34,654 Cr | 11.21 | 344.5 | 49.39% | 21.35% |
| BSE Limited | ₹1,31,779 Cr | 46.54 | 19.75 | 37.42% | 52.03% |
| GAIL (India) Ltd. | ₹1,07,805 Cr | 10.92 | 1.21 | 8.51% | 6.67% |
| One 97 Communications Ltd. | ₹1,03,771 Cr | 127.86 | 6.46 | 4.55% | 7.25% |
| Meesho Limited | ₹99,467 Cr | — | 22.66 | -28.13% | -8.68% |
| GMR Airports Limited | ₹92,090 Cr | 154.25 | 0 | -10.6% | 3.07% |
| Multi Commodity Exchange of India Ltd. | ₹77,015 Cr | 49.96 | 27.01 | 46.75% | 58.61% |
| Sun Pharma Advanced Research Company Ltd.(this company) | ₹5,574 Cr | 3.49 | 4.16 | 116.01% | 2281.85% |
AI analysis
AI-generated · google/gemini-2.5-flashSun Pharma Advanced Research Company Ltd. is listed on the Indian markets with a market capitalization of Rs 6943 Cr. The company reported an EPS of 48.23 and a P/E ratio of 4.44. The book value stands at 41.26. Return on equity (ROE) is 116.01% and return on capital employed (ROCE) is 80.89%.
Positives
- +The Return on Equity (ROE) is significantly high at 116.01%.
- +Return on Capital Employed (ROCE) is strong at 80.89%.
- +The profit margin is notably high at 3967.31% due to the reported profit in March 2026.
- +Promoter shareholding is substantial at 65.6705% as of May 31, 2026.
- +The company has no promoter shares pledged.
Negatives
- −Revenue showed a negative growth of -5%.
- −Quarterly net profits were negative for most periods, with -Rs 79.51 Cr in Dec 2024, -Rs 59.77 Cr in Mar 2025, -Rs 51.87 Cr in Jun 2025, -Rs 75.85 Cr in Sept 2025, and -Rs 80.42 Cr in Dec 2025.
- −The company is under LT-ASM Stage 1 surveillance, specifically 'LT-ASM · ASM 1'.
- −Promoter shareholding decreased from 68.4636% in Jan 2019 to 65.6705% in May 2026.
- −Revenue figures were substantially lower in preceding quarters, with Rs 14.91 Cr in Dec 2024, Rs 27.19 Cr in Mar 2025, Rs 9.64 Cr in Jun 2025, Rs 7.86 Cr in Sept 2025, and Rs 8.45 Cr in Dec 2025.
Financial Performance
The company's revenue for the quarter ended March 2026 was Rs 1853.22 Cr, with a net profit of Rs 1761.34 Cr in the same period. This indicates a significant increase compared to previous quarters, such as March 2025 where revenue was Rs 27.19 Cr and net profit was -Rs 59.77 Cr. The annual revenue for March 2026 was also Rs 1853.22 Cr, with an annual net profit of Rs 1760.7 Cr. However, overall revenue growth was -5%.
Profitability & Returns
Sun Pharma Advanced Research Company Ltd. reported a profit margin of 3967.31%. The Return on Equity (ROE) is 116.01%, and the Return on Capital Employed (ROCE) is 80.89%. The company's EPS stands at 48.23. The significant profit for the March 2026 period notably impacted these metrics.
Balance Sheet
The company maintains a debt-to-equity ratio of 0.74, indicating a moderate level of debt relative to its equity. The book value per share is Rs 41.26. There are no outstanding pledges reported against promoter shareholding.
Ownership & Pledges
The total institutional holding is 2.5685%. The number of shareholders is 137,538. There are no promoter shares pledged.
Regulatory & Surveillance
The company is currently under LT-ASM (Long Term Additional Surveillance Measure) Stage 1 surveillance, which includes multiple measures. This indicates increased monitoring by regulatory bodies to curb price manipulation and ensure market integrity.
Data as of — price: 2026-10-26 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Sun Pharma Advanced Research Company Ltd.share price & fundamentals